Noema Pharma
PrivateLast Round
Series B
Extension
Dec 11, 2024
Total Funding Raised
$241M
Company Overview
Noema Pharma operates in Healthcare & Life Sciences and is based in Basel. Its latest recorded funding round was a Series B Extension round in December 2024.
Noema Pharma is a biotechnology company that develops innovative therapeutic solutions for central nervous system conditions, particularly targeting severe neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Noema Pharma Comparables
Compare Noema Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Eumentis Therapeutics Inc. | 83% | |
| Addex Therapeutics | 82% | |
| Neurosterix | 79% |
For institutional investors. Book with your work email.
Noema Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Dec 11, 2024 | ||||
| Series B | Mar 7, 2023 | ||||
| Series A | Dec 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Noema Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioMedPartners | Series B, Series A |
| EQT Life Sciences | Series B Extension, Series B |
| Forbion | Series B |
| Gilde Healthcare | Series B, Series A, Series B Extension |
| Invus Opportunities | Series B, Series A, Series B Extension |
| Sofinnova Partners | Series B, Series B Extension, Seed, Series A |
| UPMC Enterprises | Series B, Series B Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 8, 2025
Michael Samar appointed as the new Chief Financial Officer.
- Mar 7, 2023
$147M round led by Jeito, EQT Life Sciences, and Forbion.
For institutional investors. Book with your work email.
Noema Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Noema Pharma's valuation, stock price, and market status.
Is Noema Pharma a public or private company?
Noema Pharma is a private company.
What is the current stock price of Noema Pharma?
Noema Pharma is a private company, so its shares have no public market price. Caplight tracks Noema Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Noema Pharma worth (valuation)?
Valuation information for Noema Pharma is not publicly available.
Can I buy Noema Pharma stock?
Noema Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Noema Pharma's last funding round?
Noema Pharma's most recent funding round was Series B Extension on December 11, 2024.
Who are the main investors in Noema Pharma?
Key investors in Noema Pharma include EQT Life Sciences, Forbion, Sofinnova Partners, Polaris Partners, Jeito Capital.
Will Noema Pharma IPO soon?
No public IPO plans have been announced for Noema Pharma.
How can I track Noema Pharma secondary market activity?
Caplight tracks bids, offers, and trades in Noema Pharma's shares on secondary markets.